萨库比特里尔/瓦尔沙坦治疗对心力衰竭患者的勃起功能障碍的影响
Hasan Ali Barman1, Omer Dogan2, Selim Tanyolaç1
1Department of Cardiology, Institute of Cardiology, Istanbul University-Cerrahpaşa, Istanbul, Turkey.
The American journal of cardiology
|November 20, 2023
概括
萨库比特里尔/瓦尔萨坦 (S/V) 可能会改善心力衰竭男性的性功能,心力衰竭的减少喷射率 (HFrEF). 这项研究在S/V治疗一个月后观察到勃起功能有所改善.
科学领域:
- 心脏病学 心脏病学
- 药理学 药理学是指药理学的学科.
- 泌尿器科 泌尿器科 泌尿器科 泌尿器科
背景情况:
- 慢性心力衰竭与减少喷射分数 (HFrEF) 显著影响患者的生活质量.
- 勃起功能障碍 (ED) 是患有HFrEF的男性常见的并发症.
- 萨库比特里尔/瓦尔萨坦 (S/V),一种血管激素受体-内普利辛抑制剂,已被确立用于HFrEF管理.
研究的目的:
- 评估萨库比特里尔/瓦尔沙坦 (S/V) 在治疗高勃起功能障碍 (ED) 的男性患者中的疗效.
- 用国际勃起功能指数 (IIEF) 问卷来评估性活动和ED严重程度的变化.
主要方法:
- 一项前性,开放性研究,涉及59名被诊断患有HFrEF和ED的男性患者.
- 患者接受了S/V治疗一个月.
- 在基线和一个月后评估了IIEF评分和临床参数.
主要成果:
- 在治疗后观察到IIEF得分的统计学上显著增加,表明ED严重程度降低.
- 在一个月后的随访中,人们注意到性活动的改善.
- 虽然IIEF得分的增加在统计学上显著,但没有达到临床意义.
结论:
- 萨库比特里尔/瓦尔萨坦 (S/V) 治疗可能为患有HFrEF的男性的性功能提供好处.
- 需要进一步的研究来证实这些发现的临床意义.
- 在HFrEF患者中,S/V显示出作为治疗选择的潜力,解决心血管和性健康问题.
相关概念视频
01:26Heart Failure Drugs: Inhibitors of Renin-Angiotensin System
436
The activation of the sympathetic nervous system and the renin-angiotensin-aldosterone system (RAAS) contributes to cardiac remodeling, and inhibiting the RAAS is a pharmacological target in heart failure management. As a result, neurohumoral modulation is a crucial treatment principle for managing heart failure. This approach involves using medications like ACE inhibitors (ACEIs), angiotensin receptor blockers (ARBs), β-blockers, mineralocorticoid receptor antagonists (MRAs), and neutral...
436
01:28Treatment for Pulmonary Arterial Hypertension: Phosphodiesterase Inhibitors
162
Phosphodiesterase 5 (PDE5) inhibitors are potent enzymes that function to hydrolyze cyclic nucleotides to their corresponding 5' monophosphates. Their unique biochemical properties have been applied in treating Pulmonary Arterial Hypertension (PAH).
Among the PDE5 inhibitors, sildenafil (Revatio) stands out as a competitive and selective inhibitor. It operates by elevating cellular levels of cGMP and augmenting signaling through the cGMP-PKG pathway, promoting vasodilation. Upon oral...
Among the PDE5 inhibitors, sildenafil (Revatio) stands out as a competitive and selective inhibitor. It operates by elevating cellular levels of cGMP and augmenting signaling through the cGMP-PKG pathway, promoting vasodilation. Upon oral...
162
01:22Heart Failure Drugs: Diuretics
398
Heart failure and kidney perfusion are interconnected in a complex way. Reduced renal perfusion and venous congestion are two significant factors that contribute to renal dysfunction in heart failure. The kidneys, primarily responsible for fluid balance in the body, are adversely affected due to compromised cardiac output and increased venous pressure. In response to reduced renal perfusion, the kidneys activate neurohumoral mechanisms to restore balance. However, these mechanisms can be...
398
01:22Heart Failure Drugs: β-Blockers
344
β-adrenergic antagonists, commonly known as β-blockers, block the effects of sympathetic neurotransmitters such as noradrenaline (NA) and adrenaline (ADR). They have several beneficial effects in heart failure treatment. They reduce heart rate, the force of contraction, and cardiac muscle relaxation. They also slow the atrial-ventricular conduction rate and raise the threshold for arrhythmias. The concentration of β-blockers determines their effects on bronchodilation,...
344
01:18Treatment for Pulmonary Arterial Hypertension: Endothelin Receptor Antagonists
171
Endothelins (ETs) are potent vasoactive peptides critical in the human body's various physiological and pathological processes. One of the most promising therapeutic strategies for treating pulmonary arterial hypertension (PAH) involves counteracting the effects of these endothelins using a class of drugs known as endothelin receptor antagonists.
ETs are synthesized through a complex sequence of enzymatic steps, primarily involving an enzyme referred to as endothelin-converting enzyme...
ETs are synthesized through a complex sequence of enzymatic steps, primarily involving an enzyme referred to as endothelin-converting enzyme...
171
01:30Antihypertensive Drugs: Angiotensin II Receptor Blockers
748
In the renin-angiotensin-aldosterone system, a hormone called angiotensin II plays a crucial role. It binds to the AT1 receptors in vascular smooth muscles coupled with Gq proteins. The activation of these receptors activates an enzyme called phospholipase C, which releases two molecules: inositol trisphosphate and diacylglycerol. These molecules cause a chain reaction that leads to the phosphorylation of myosin light chains and promotes interaction between actin and myosin, leading to smooth...
748